QIAGEN slides after cutting 2026 outlook, citing weaker QuantiFERON demand and cautious customer spending

QIAGEN N.V. (QGEN) is down 10.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears tied to QIAGEN lowering its full-year 2026 outlook after reporting mixed preliminary Q1 results. Investors may be reacting less to profitability (which was in line) and more to softer sales trends and a weaker near-term revenue outlook, particularly in the company’s QuantiFERON tuberculosis franchise.

Details:

QIAGEN posted preliminary Q1 2026 net sales of $492 million, which was down 1% at constant exchange rates versus its prior expectation for at least modest constant-currency growth.

QuantiFERON sales declined 5% at constant exchange rates to $113 million, with the company pointing to a significant drop in immigration testing demand in the U.S. and the Middle East.

QIAGEN cut its 2026 outlook to about 1%–2% constant-currency net sales growth (previously at least 5%) and lowered expected adjusted diluted EPS to at least $2.43 (previously at least $2.50).

For Q2 2026, QIAGEN guided to an approximately 2% constant-currency sales decline year over year, with adjusted diluted EPS expected to be at least $0.60.

Sources:

QIAGEN Investor Relations, BioSpace, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive QGEN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$QGEN Hedge Fund Activity

We have seen 146 institutional investors add shares of $QGEN stock to their portfolio, and 141 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

AMUNDI removed 4,290,273 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $192,933,576
BANK OF AMERICA CORP /DE/ removed 3,271,845 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $147,134,869
VICTORY CAPITAL MANAGEMENT INC removed 1,656,165 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $74,477,740
CITIGROUP INC added 1,173,007 shares (+493.0%) to their portfolio in Q4 2025, for an estimated $52,750,124
DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN removed 1,154,988 shares (-53.6%) from their portfolio in Q4 2025, for an estimated $51,939,810
ILEX CAPITAL PARTNERS (UK) LLP added 1,020,725 shares (+inf%) to their portfolio in Q4 2025, for an estimated $45,902,003
PRICE T ROWE ASSOCIATES INC /MD/ added 906,589 shares (+12.1%) to their portfolio in Q4 2025, for an estimated $40,769,307

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$QGEN Price Targets

Multiple analysts have issued price targets for $QGEN recently. We have seen 5 analysts offer price targets for $QGEN in the last 6 months, with a median target of $54.0.

Here are some recent targets:

Luke Sergott from Barclays set a target price of $44.0 on 04/14/2026
Jan Koch from Deutsche Bank set a target price of $54.0 on 03/13/2026
Daniel Arias from Stifel set a target price of $50.0 on 02/06/2026
Patrick Donnelly from Citigroup set a target price of $55.0 on 02/06/2026
Casey Woodring from JP Morgan set a target price of $60.0 on 02/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.